The efficacy and safety of neoadjuvant camrelizumab and chemotherapy for locally advanced thoracic esophageal squamous cell carcinoma

doi:10.1200/JCO.2022.40.4_suppl.278

	The efficacy and safety of neoadjuvant camrelizumab and chemotherapy for locally advanced thoracic esophageal squamous cell carcinoma
	Xu, Weili ; Jiang, Youhua ; Wang, Changchun ; Wu, Jie ; Li, Jianqiang ; Hu, Yuqian ; Lu, Weishan ; Shen, Dijian ; Wang, Yinjie ; Chen, Qixun
刊名	JOURNAL OF CLINICAL ONCOLOGY
	2022-02-01
卷号	40
ISSN号	0732-183X
DOI	10.1200/JCO.2022.40.4_suppl.278
资助项目	[JBZX-202006]
WOS研究方向	Oncology
语种	英语
出版者	LIPPINCOTT WILLIAMS & WILKINS
WOS记录号	WOS:000770995900270
内容类型	期刊论文
源URL	[http://ir.hfcas.ac.cn:8080/handle/334002/128681]
专题	中国科学院合肥物质科学研究院
作者单位	1.Univ Chinese Acad Sci, Canc Hosp, Hengzhou, Peoples R China 2.Univ Chinese Acad Sci, Canc Hosp, Hangzhou, Peoples R China
推荐引用方式 GB/T 7714	Xu, Weili,Jiang, Youhua,Wang, Changchun,et al. The efficacy and safety of neoadjuvant camrelizumab and chemotherapy for locally advanced thoracic esophageal squamous cell carcinoma[J]. JOURNAL OF CLINICAL ONCOLOGY,2022,40.
APA	Xu, Weili.,Jiang, Youhua.,Wang, Changchun.,Wu, Jie.,Li, Jianqiang.,...&Chen, Qixun.(2022).The efficacy and safety of neoadjuvant camrelizumab and chemotherapy for locally advanced thoracic esophageal squamous cell carcinoma.JOURNAL OF CLINICAL ONCOLOGY,40.
MLA	Xu, Weili,et al."The efficacy and safety of neoadjuvant camrelizumab and chemotherapy for locally advanced thoracic esophageal squamous cell carcinoma".JOURNAL OF CLINICAL ONCOLOGY 40(2022).